Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -102.86% is 44% above its 5-year average of -184.55%, near the high end of its 5-year range (-393.60%–-74.86%).
33.76% below its 12-month average of -76.90%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -22.36%.
RETURN ON ASSETS (ROA)
-102.86%
RETURN ON ASSETS (ROA) AVG TTM
-76.90%
RETURN ON ASSETS (ROA) AVG 3Y
-95.53%
RETURN ON ASSETS (ROA) AVG 5Y
-184.55%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-33.76%
CURRENT VS 3Y AVG
-7.68%
CURRENT VS 5Y AVG
+44.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.47%
median of 682 covered companies
CURRENT VS SECTOR MEDIAN
-237.58%
vs the sector median at left
Lucyd, Inc
Market Cap
$5.86M
Return on Assets (ROA)
-102.86%
TTM Avg
-76.90%
3Y Avg
-95.53%
5Y Avg
-184.55%
Market Cap
$5.99M
Return on Assets (ROA)
83.82%
TTM Avg
-0.56%
3Y Avg
-31.49%
5Y Avg
-28.41%
Market Cap
$5.96M
Return on Assets (ROA)
-69.39%
TTM Avg
-57.20%
3Y Avg
-55.49%
5Y Avg
-56.22%
Market Cap
$5.69M
Return on Assets (ROA)
-54.95%
TTM Avg
-72.19%
3Y Avg
-72.80%
5Y Avg
-69.14%
Market Cap
$6.01M
Return on Assets (ROA)
-81.62%
TTM Avg
-81.33%
3Y Avg
-106.24%
5Y Avg
-102.80%
Market Cap
$5.51M
Return on Assets (ROA)
-68.33%
TTM Avg
-234.58%
3Y Avg
-196.81%
5Y Avg
-171.01%
Market Cap
$6.31M
Return on Assets (ROA)
-99.97%
TTM Avg
-120.54%
3Y Avg
-89.96%
5Y Avg
-79.52%
Market Cap
$6.27M
Return on Assets (ROA)
-55.85%
TTM Avg
-69.75%
3Y Avg
-63.38%
5Y Avg
-59.39%
Market Cap
$5.32M
Return on Assets (ROA)
-30.94%
TTM Avg
-24.01%
3Y Avg
-19.50%
5Y Avg
-23.56%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucyd, Inc (LUCY) | $5.86M | -102.86% | -76.90% | -95.53% | -184.55% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.99M | 83.82% | -0.56% | -31.49% | -28.41% |
| enVVeno Medical Corporation (NVNO)vs › | $5.96M | -69.39% | -57.20% | -55.49% | -56.22% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.69M | -54.95% | -72.19% | -72.80% | -69.14% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.01M | -81.62% | -81.33% | -106.24% | -102.80% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.51M | -68.33% | -234.58% | -196.81% | -171.01% |
| Femasys Inc. (FEMY)vs › | $6.31M | -99.97% | -120.54% | -89.96% | -79.52% |
| Biomerica, Inc. (BMRA)vs › | $6.27M | -55.85% | -69.75% | -63.38% | -59.39% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -30.94% | -24.01% | -19.50% | -23.56% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | -106.49% | -259.99% | -586.63% | -434.16% |
ROA
-102.9%
ROE
-111.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -74.86% |
| 2024-12-31 | -78.94% |
| 2023-12-31 | -107.15% |
| 2022-12-31 | -121.15% |
| 2021-12-31 | -393.60% |
| 2020-12-31 | -331.60% |
| 2019-12-31 | 0.00% |
